Scienmag

DECEMBER 16, 2020

Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

Drug Discovery World

JANUARY 12, 2024

The top stories: Excitement over new antibiotics that can kill drug-resistant bacteria A novel antibiotic class targeting a major global pathogen and threat to human health has been discovered by scientists from Roche and Harvard University (Cambridge, MA, US).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

Scienmag

AUGUST 21, 2020

While antibodies may fade fast, T cells appear to be long-lived and might confer lasting immunity.

Immune Response 40

Immune Response Antibody Scientist Allergies 40

Delveinsight

AUGUST 6, 2020

By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus. Scientists have already isolated many highly potent neutralizing antibodies from patients who recovered from COVID-19. FDA turns back peanut allergy patch of DBV Technologies.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

XTalks

JANUARY 20, 2021

Researchers at KU Leuven in Belgium have found a potential mechanism underlying irritable bowel syndrome (IBS) that involves activation of immune cells primed by past gastrointestinal infections. However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease.

Immune Response 52

Immune Response Research Allergies Protein 52

The Pharma Data

MARCH 13, 2022

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

Immune Response 52

Immune Response Protein Medicine Genetics 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53